Digital Pathology Market

The global Digital Pathology Market is valued at USD 1.15 Billion in 2024 and is projected to reach a value of USD 6.55 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 17.15% between 2025 and 2035.

Premium Insights

Chronic and infectious diseases include cardiovascular, cancer, diabetes, influenza, orthopedic, and neurological conditions have become more prevalent worldwide, placing an increased load on healthcare systems and significantly affecting peoples physical and mental wellbeing. For instance, according to a report by British Heart Foundation in January 2022, there were about 7.6 million persons in the UK who had heart disease as a result of cardiovascular illnesses (CVDs). The market is expanding as a result of the increased prevalence of cardiovascular illnesses and the growing demand for novel technologies that can diagnose these conditions.

• The quick sharing of whole slides to several pathologists is a feature of digital pathology platforms that allows them to instantly contribute to a case at once. For instance, Roche announced the introduction of CE-IVDs automated digital pathology algorithms, uPath HER2 (4B5) image analysis, and uPath HER2 Dual ISH image analysis for breast cancer to assist in determining the optimum treatment plan for each patient. This is accelerating market expansion as well.
• North America generated more than 41.3% of revenue share in 2022
• Asia Pacific is expected to grow at the quickest rate from 2023 to 2030
• Scanners segment accounted for the largest market growth. It contributed over 35.5% of the total revenue share in 2022
• Human Pathology segment revealed the most significant market growth, contributing more than 74.2% of the total revenue share in 2022
• Drug Discovery segment accounts for largest revenue of 30.2% in 2022
• Pharmaceutical & Biotechnology Companies will account for largest share of 34.8% in 2022

Economic Insights

The Digital Pathology has grown significantly. The rising incidence of chronic diseases—of which cancer alone affects millions of people worldwide—can be related to this strong increase. The use of digital pathology technologies has also shown the potential for up to 30% in cost reductions in pathology laboratory operations. Additionally, the incorporation of AI and machine learning in digital pathology is anticipated to considerably contribute to market expansion, with tools powered by AI reportedly assisting pathologists in making diagnoses up to 22% more accurately.

Top Market Trends

• Increasing demand for accuracy and precision in pathology: Better patient outcomes may result from pathologists using digital pathology to produce more precise and accurate diagnosis.
• Growing awareness of the benefits of digital pathology: The advantages of digital pathology, such as greater collaboration, increased efficiency, and decreased costs, are becoming more and more clear to pathologists and other healthcare practitioners.
• Technological advancements: Digital pathology is becoming more widely available and more reasonably priced due to technological developments like the creation of tools that are powered by artificial intelligence (AI).
• Increasing adoption of digital pathology in clinical practice: Diagnostic efficiency and accuracy are evolving as digital pathology is being used more frequently in clinical practice. Pathologists can improve accuracy and enable remote consultations and telepathology by analysing digital images of tissue samples on computer displays.
• Drug Discovery and Research Applications: Pharmaceutical and biotechnology firms were increasingly using digital pathology for biomarker discovery, preclinical and clinical research, and medication discovery. High-throughput image analysis and data management were made possible.

Market Segmentation

Digital Pathology {{Segmentation_Ext}}

Based on Product

Scanners holds the largest share

The Digital Pathology market is expected to be dominated by the scanners segment because they are essential instruments for transforming tissue slides into digital images that pathologists then examine using software for digital pathology. They are essential elements that have a significant impact on the precision and effectiveness of digital pathology workflows, and their rising sophistication and accessibility have sped up adoption across the globe in pathology labs.

Based on Type

Human Pathology will dominate the market during Forecast Period

The Digital Pathology market is anticipated to be dominated by the human pathology segment due to the increasing prevalence of chronic diseases, particularly cancer, the demand for pathology services has increased. Digital pathology holds the potential of increased diagnostic accuracy and precision, which will improve patient outcomes.

Based on Application

Drug Discovery lead the market

Drug discover has dominated the Digital Pathology market due to the growing need for novel medications and treatments, driven by the altering healthcare environment, is compatible with digital pathologys ability to speed up the process of drug discovery. It plays a crucial part in expediting research at every stage, from preclinical analysis to clinical trials. A further indication of digital pathologys vital role in expediting innovation and the creation of ground-breaking pharmaceutical solutions is the industrys growing embrace of it, which has made it the center of developments in drug discovery.

Based on End-user

Pharmaceutical & Biotechnology Companies will account for largest market share

In terms of end-users, pharmaceutical & biotechnology are anticipated to hold the greatest market share for Digital Pathology because the global demand for cutting-edge medications and therapies is rising, and digital pathologys ability to speed up the drug discovery and development process. The importance of this technology in increasing research productivity, from early-stage drug screening to clinical trials, cannot be overstated.

Based on Region

North America will lead the market

North America is expected to dominate the market for Digital Pathology because the region has a significant demand for advanced pathology services due to the large prevalence of chronic disorders, most notably cancer. Additionally, North America is a leader in accepting digital pathology solutions due to its propensity for early technological adoption. Government measures that are supportive, particularly those that promote telepathology and healthcare digitization, reinforce its leadership. Furthermore, North America is home to numerous industry giants, including Philips and Leica Biosystems, which help the continent maintain a dominant position in the rapidly changing field of digital pathology.

Competitive Landscape

The constant interaction between well-established industry leaders and cutting-edge newcomers characterizes the competitive environment of the Digital Pathology market. Industry leaders distinguishes out by providing a full range of digital pathology solutions, including scanners, software, and AI-driven analysis tools, to meet laboratory and healthcare needs. With its wide range of digital pathology products, such as whole slide scanners, image analysis software, and workflow automation solutions, Leica Biosystems, a Danaher subsidiary, has a sizable market share. Technological advancement, the incorporation of AI, and the pursuit of improved diagnostic accuracy in healthcare continue to alter the changing landscape.

The players in the global Digital Pathology market include Leica Biosystems (US) among others.

Recent Market Developments

• June 2022: The VENTANA DP 600 slide scanner for digital pathology was introduced by F. Hoffmann-LA Roche Itd., improving patient care through accurate diagnosis.
• September 2022: Maintaining file compatibility between the Leica Biosystems Aperio GT 450 series of scanners and the Indica Labs Halo range of software solutions allowed Danaher Corporation and Indica Labs to collaborate on the delivery of compatible digital pathology workflow solutions.
• 2022: The NanoZoomer S360MD Slide scanner system from Hamamatsu has been given US FDA 510(k) clearance for primary diagnostic use.

Segmentation of the Global Digital Pathology Market